COMMUNIQUÉS West-GlobeNewswire

Summit Therapeutics plc : Notice of Results
09/04/2018
Summit Therapeutics plc ("Summit", the "Company", or the "Group") Summit Therapeutics Provides Notice of Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2018 Oxford, UK, and Cambridge, MA, US, [...]
Scythian Biosciences Corp. Announces Progression of Global Expansion Efforts with Letter of Intent to Acquire MMJ Colombia Partners Inc.
09/04/2018
– Closing of the Acquisition will strengthen Scythian’s Latin American platform with three Colombian cannabis licences including for cultivation of CBD, THC and extraction of cannabis derivatives – – Colombian native Mr [...]
Wildflower Re “Brands”
09/04/2018
VANCOUVER, British Columbia, April 09, 2018 (GLOBE NEWSWIRE) -- Wildflower Marijuana Inc. (CSE:SUN) (the “Company”) held its Annual and Special Meeting on April 6 where shareholders overwhelming approved to change the [...]
Medtronic Announces Renal Denervation Pivotal Trial for the Treatment of Hypertension
09/04/2018
Pivotal Trial Now Underway to Study Effect of Investigational Procedure in Patients with High Blood Pressure DUBLIN - April 9, 2018 - Medtronic plc (NYSE: MDT ) today announced U.S. Food and Drug Administration (FDA) [...]
OrthoPediatrics Corp. Announces Sponsorship of 2018 EPOS Meeting and Lunch Symposium
09/04/2018
WARSAW, Ind., April 09, 2018 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (NASDAQ: KIDS ), a company exclusively focused on advancing the field of pediatric orthopedics, today announced it will continue its Diamond [...]
Canada House Announces Appointment of Chief Financial Officer
09/04/2018
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, April 09, 2018 (GLOBE NEWSWIRE) -- Canada House Wellness Group Inc. (CSE:CHV) (“Canada House” or the “Company”) today [...]
Data Monitoring Committee (DMC) Completes Planned Safety and Data Review of Celsion’s Phase III OPTIMA Study of ThermoDox® in Primary Liver Cancer
09/04/2018
DMC Unanimously Recommends Continuation of OPTIMA Study Based on Safety Data From 411 Patients; Enrollment Now at 80% Blinded Progression-Free Survival (PFS) Rate in the OPTIMA Study is Consistent With the Subgroup [...]
Precision Therapeutics, Inc. Engages Richard Gabriel to Drive Business Development Strategy for its TumorGenesis Subsidiary
09/04/2018
Richard Gabriel, BS, MBA is a board member of Precision Therapeutics and spearheaded the licensing of new technologies for 3D cell culturing from 48 Hour Discovery, SyntArray and CellBridge MINNEAPOLIS, April 09, 2018 ( [...]
Physeon Selects RCRI for Pivotal Study of Veinplicity Device
09/04/2018
Recent Clinical Trial Indicated Device had a Dilatory Effect 38% Greater than Standard of Care SCHAFFHAUSEN, Switzerland, April 09, 2018 (GLOBE NEWSWIRE) -- Physeon GmbH (“Physeon” or the “Company”), a leading developer [...]
Minerva Neurosciences Screens First Patient in Phase 2b Trial of MIN-117 to Treat Major Depressive Disorder
09/04/2018
Multi-center trial to enroll approximately 324 patients at approximately 40 clinical sites in U.S. and Europe WALTHAM, Mass., April 09, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV ), a clinical- [...]
EyeGate Receives FDA Feedback on Investigational Device Exemption Amendment for Second Pilot Study of Ocular Bandage Gel
09/04/2018
Feedback Provides Clear Path to Resubmission; Expected July 2018 WALTHAM, Mass., April 09, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG ) (“EyeGate” or the “Company”), a clinical-stage, specialty [...]
OncoMed to Present Multiple Preclinical Abstracts Related to Immuno-Oncology Programs at the 2018 American Association for Cancer Research Annual Meeting
09/04/2018
REDWOOD CITY, Calif., April 09, 2018 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ: OMED ), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, [...]
Genocea to Present Data at Upcoming AACR Annual Meeting Further Highlighting ATLAS Platform Ability to Identify and Characterize Neoantigens for Cancer Vaccines
09/04/2018
CAMBRIDGE, Mass., April 09, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc . (NASDAQ: GNCA ), a biopharmaceutical company developing neoantigen cancer vaccines, today announced upcoming presentations at the 2018 [...]
Avid Bioservices to Participate at INTERPHEX 2018
09/04/2018
TUSTIN, Calif., April 09, 2018 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO ) (NASDAQ: CDMOP ), a dedicated contract development and manufacturing organization (CDMO) working to improve patient lives by [...]
Delcath Announces Shareholder Approval of Consent Solicitation
09/04/2018
NEW YORK, April 09, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that shareholders have [...]
Mersana Therapeutics Announces Poster Presentations Demonstrating Differentiating Aspects of ADC Platform Technology at the American Association for Cancer Research Annual Meeting 2018
09/04/2018
CAMBRIDGE, Mass., April 09, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN ), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates ( [...]
Maple Leaf Enters “Active Review” with Health Canada on its ACMPR Application
09/04/2018
CALGARY, Alberta, April 09, 2018 (GLOBE NEWSWIRE) -- Maple Leaf Green World Inc. (“ Maple Leaf ” or the “ Company ”) (TSX-V: MGW ) (OTCQB:MGWFF) is pleased to announce that its application to become a licenced producer [...]
VANC Announces Exclusive Sales Broker Agreement With Pinnacle Pharmaceutics
09/04/2018
VANCOUVER, British Columbia, April 09, 2018 (GLOBE NEWSWIRE) -- VANC Pharmaceuticals Inc. (“VANC”) (TSXV:VANC) (OTCQB:NUVPF) is pleased to announce that it has entered into a sales broker agreement with Pinnacle [...]
VBL Therapeutics Awarded $2.5 Million Non-Dilutive Grant by the Israel Innovation Authority
09/04/2018
TEL AVIV, Israel, April 09, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ) today announced that it has been awarded a grant of 8.9 million New Israeli Shekels (approximately $2.5 million) by the Israel [...]

Pages